Business
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
About this update from Icecure Medical Ltd.
[{"type":"text","content":"At the annual European Conference on Interventional Oncology, ICESECRET data presented demonstrated 89.4% recurrence-free rate in patients with tumors ≤3 cm and 83.9% of patients remained recurrence-free at a median follow-up of 4.0 yearsIndependent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes Independent study showed 92.9% reduction in fibroadenoma volume at 12 months post-treatment with ProSense®FDA clearance of ProSense® in early-stage breast cancer drives expanding global adoption and clinical interest in breast cryoablationCAESAREA, Israel, May 19, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (\"IceCure\", \"IceCure Medical\" or the \"Company\"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that cryoablation and ProSense® were featured at the annual European Conference on Interventional Oncology (\"ECIO\") 2026, held in Basel, Switzerland on April 26 to 30, 2026.\n\"We believe ECIO 2026 marked a significant milestone for IceCure, ProSense® and cryoablation in interventional oncology,\" said Eyal Shamir, Chief Executive Officer of IceCure. \"We are experiencing growing global momentum and commercial interest in ProSense® and cryoablation, with particular interest shown at ECIO 2026 in the treatment of breast cancer, fibroadenomas, and kidney cancer. The eager participation of doctors who are regular users of ProSense® leading hands-on trainings and presentations and more independent third-party data, combined with the compelling kidney cancer results from the ICESECRET trial, reinforce the expanding clinical validation and versatility of our technology.\"For the first time in ECIO's history, a dedicated breast cryoablation course was held, including hands-on training with ProSense® conducted by leading ProSense® users: Dr. Franco Orsi of the European Institute of Oncology, Milan and Principal Investigator of the PRECICE trial, Dr. Toulsie Ramothul of Institute Curie and Principal Investigator of the CRYODESC trial, and Dr. Linda Riks of the Franciscus Gasthuis & Vlietland Hospital, Rotterdam, Investigator of the THERMAC trial. In addition, ProSense® was featured in three general cryoablation device hands-on training se...